Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury.

[1]  M. Goligorsky,et al.  Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. , 2010, American journal of physiology. Renal physiology.

[2]  R. Bloom,et al.  Posttransplant anemia in solid organ recipients. , 2010, Transplantation reviews.

[3]  G. Heinze,et al.  Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study , 2009, BMJ : British Medical Journal.

[4]  P. Jablonski,et al.  The Contribution of Podocytes to Chronic Allograft Nephropathy , 2008, Nephron Experimental Nephrology.

[5]  A. Cerami,et al.  Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response , 2008, Journal of internal medicine.

[6]  F. Kuralay,et al.  Protective effect of Epo on oxidative renal injury in rats with cyclosporine nephrotoxicity , 2008, Pediatric Nephrology.

[7]  L. Gallon,et al.  Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[8]  M. Arcasoy.  The non‐haematopoietic biological effects of erythropoietin , 2008, British journal of haematology.

[9]  M. Juntilla,et al.  Critical roles of the PI3K/Akt signaling pathway in T cell development. , 2008, Immunology letters.

[10]  B. Kasiske,et al.  Chronic allograft nephropathy , 2008, Current opinion in nephrology and hypertension.

[11]  A. Jevnikar,et al.  Late kidney allograft loss: what we know about it, and what we can do about it. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[12]  T. Fabian,et al.  Efficacy and safety of epoetin alfa in critically ill patients. , 2007, The New England journal of medicine.

[13]  S. Shankland,et al.  Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. , 2007, Kidney international.

[14]  M. Nangaku,et al.  Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. , 2007, Kidney international.

[15]  N. Ichimaru,et al.  Erythropoietin Protects the Kidneys Against Ischemia Reperfusion Injury by Activating Hypoxia Inducible Factor-1α , 2007, Transplantation.

[16]  M. Novak,et al.  Anemia Is Associated with Mortality in Kidney‐Transplanted Patients—A Prospective Cohort Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  R. Colvin,et al.  Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’) , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  M. Kitamura,et al.  Transcriptional suppression of nephrin in podocytes by macrophages: Roles of inflammatory cytokines and involvement of the PI3K/Akt pathway , 2007, FEBS letters.

[19]  M. Lebel,et al.  Renin-Angiotensin-Aldosterone System Antihypertensive and Renal Protective Effects of Renin-Angiotensin System Blockade in Uremic Rats Treated With Erythropoietin , 2006 .

[20]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[21]  A. Piccoli,et al.  A Role for Heme Oxygenase-1 in the Antioxidant and Antiapoptotic Effects of Erythropoietin: The Start of a Good News/Bad News Story? , 2006, Nephron Physiology.

[22]  L. Zentilin,et al.  Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  Z. Endre,et al.  Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. , 2006, Kidney international.

[24]  I. Macdougall,et al.  Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors , 2006, Transplantation.

[25]  S. Glaser,et al.  Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[26]  Takashi Urano,et al.  Angiopoietins and angiopoietin-like proteins in angiogenesis. , 2006, Endothelium : journal of endothelial cell research.

[27]  M. Kretzler,et al.  Differential Expression of Profibrotic and Growth Factors in Chronic Allograft Nephropathy , 2006, Transplantation.

[28]  D. Stolz,et al.  Low-dose carbon monoxide inhalation prevents development of chronic allograft nephropathy. , 2006, American journal of physiology. Renal physiology.

[29]  M. Nangaku.  Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[30]  浦尾 紀文.  Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia , 2006 .

[31]  N. Gretz,et al.  Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. , 2006, Kidney international.

[32]  M. Schiffer,et al.  Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. , 2006, Diabetes.

[33]  K. Nakao,et al.  Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[34]  Cees van Kooten,et al.  Chronic renal allograft rejection: pathophysiologic considerations. , 2005, Kidney international.

[35]  Chul-woo Yang,et al.  Attenuation of Interstitial Inflammation and Fibrosis by Recombinant Human Erythropoietin in Chronic Cyclosporine Nephropathy , 2005, American Journal of Nephrology.

[36]  P. Halloran,et al.  Assessing Long‐Term Nephron Loss: Is It Time to Kick the CAN Grading System? , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  K. Siamopoulos,et al.  Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. , 2004, Kidney international.

[38]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[39]  D. Fliser,et al.  Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure , 2004, Circulation.

[40]  David W. Johnson,et al.  Erythropoietin protects against ischaemic acute renal injury. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  Tetsuhiro Tanaka,et al.  Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of Bax. , 2003, Biochemical and biophysical research communications.

[42]  A. Alcaraz,et al.  Use of recombinant human erythropoietin in kidney transplant patients with stable graft function. , 2003, Transplantation proceedings.

[43]  M. Tapolyai,et al.  r.hu-Erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline , 2003, BMC nephrology.

[44]  A. Weiss,et al.  The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3 , 2003, Immunological reviews.

[45]  D. Heisey,et al.  Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  H. van Goor,et al.  Expression of Inducible and Endothelial Nitric Oxide Synthases, Formation of Peroxynitrite and Reactive Oxygen Species in Human Chronic Renal Transplant Failure , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  S. Harper,et al.  Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. , 2002, Journal of the American Society of Nephrology : JASN.

[48]  N. Perico,et al.  Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. , 2001, Journal of the American Society of Nephrology : JASN.

[49]  J. Hughes,et al.  Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. , 2001, Journal of the American Society of Nephrology : JASN.

[50]  R. Colvin,et al.  Rejection of peritubular capillaries in renal allo‐ and xeno‐grafts , 2000, Clinical transplantation.

[51]  J. Norman,et al.  Hypoxia-Induced Changes in Extracellular Matrix Metabolism in Renal Cells , 1999, Nephron Experimental Nephrology.

[52]  K. Nitta,et al.  Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. , 1999, European journal of pharmacology.

[53]  C. Westenfelder,et al.  Human, rat, and mouse kidney cells express functional erythropoietin receptors. , 1999, Kidney international.

[54]  R. Ettenger,et al.  Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction , 1998, Pediatric Nephrology.

[55]  J. van den Born,et al.  Hydroxyl Radicals Depolymerize Glomerular Heparan Sulfate in Vitro and in Experimental Nephrotic Syndrome* , 1997, The Journal of Biological Chemistry.

[56]  J. Thompson,et al.  Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Fontanellas,et al.  Long-term erythropoietin in rats with reduced renal mass. , 1996, Nephron.

[58]  R. Carlini,et al.  Recombinant human erythropoietin stimulates angiogenesis in vitro. , 1995, Kidney international.

[59]  N. Perico,et al.  Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. , 1995, Kidney international.

[60]  M. Rudnick,et al.  Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[61]  P. Jablonski,et al.  Expression and distribution of epidermal growth factor in acute and chronic renal allograft rejection. , 1994, Kidney international.

[62]  T. Sundt,et al.  INDUCTION OF SPECIFIC TOLERANCE TO CLASS I‐DISPARATE RENAL ALLOGRAFTS IN MINIATURE SWINE WITH CYCLOSPORINE , 1992, Transplantation.

[63]  M. Wehrmann,et al.  The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. , 1990, Pathology, research and practice.

[64]  B. Brenner,et al.  Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. , 1988, Proceedings of the National Academy of Sciences of the United States of America.